questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Gènes modificateurs
Gènes modificateurs : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes modificateurs : Questions médicales les plus fréquentes",
"headline": "Gènes modificateurs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes modificateurs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes modificateurs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gènes",
"url": "https://questionsmedicales.fr/mesh/D005796",
"about": {
"@type": "MedicalCondition",
"name": "Gènes",
"code": {
"@type": "MedicalCode",
"code": "D005796",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes modificateurs",
"alternateName": "Genes, Modifier",
"code": {
"@type": "MedicalCode",
"code": "D060045",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Harriet Corvol",
"url": "https://questionsmedicales.fr/author/Harriet%20Corvol",
"affiliation": {
"@type": "Organization",
"name": "Sorbonne Université, Inserm U938, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France."
}
},
{
"@type": "Person",
"name": "Yuanjian Chen",
"url": "https://questionsmedicales.fr/author/Yuanjian%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Fuyi Xu",
"url": "https://questionsmedicales.fr/author/Fuyi%20Xu",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Robert W Williams",
"url": "https://questionsmedicales.fr/author/Robert%20W%20Williams",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Syamal K Bhattacharya",
"url": "https://questionsmedicales.fr/author/Syamal%20K%20Bhattacharya",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.",
"datePublished": "2022-10-17",
"url": "https://questionsmedicales.fr/article/36251860",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13506129.2022.2131384"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.",
"datePublished": "2024-09-13",
"url": "https://questionsmedicales.fr/article/39346594",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2024.1385089"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reward network dysfunction is associated with cognitive impairment after stroke.",
"datePublished": "2023-05-31",
"url": "https://questionsmedicales.fr/article/37307650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nicl.2023.103446"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction one-year post COVID-19.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36603126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/neu0000876"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36729842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/RHU.0000000000001888"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes modificateurs",
"item": "https://questionsmedicales.fr/mesh/D060045"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes modificateurs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes modificateurs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes modificateurs",
"description": "Comment identifier les gènes modificateurs ?\nQuels tests sont utilisés pour les gènes modificateurs ?\nLes gènes modificateurs sont-ils testés en routine ?\nPeut-on détecter les gènes modificateurs par imagerie ?\nQuel rôle jouent les gènes modificateurs dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Cognitive+Dysfunction&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes modificateurs",
"description": "Les gènes modificateurs affectent-ils les symptômes ?\nQuels symptômes sont liés aux gènes modificateurs ?\nLes gènes modificateurs causent-ils des symptômes ?\nPeut-on prédire les symptômes avec des gènes modificateurs ?\nLes gènes modificateurs sont-ils liés à des symptômes spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Cognitive+Dysfunction&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes modificateurs",
"description": "Peut-on prévenir les effets des gènes modificateurs ?\nY a-t-il des mesures préventives spécifiques ?\nLes gènes modificateurs nécessitent-ils une prévention ciblée ?\nComment la recherche aide-t-elle à la prévention ?\nLes gènes modificateurs influencent-ils le mode de vie préventif ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Cognitive+Dysfunction&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes modificateurs",
"description": "Les traitements ciblent-ils les gènes modificateurs ?\nComment les gènes modificateurs influencent-ils le traitement ?\nY a-t-il des traitements spécifiques pour les gènes modificateurs ?\nLes gènes modificateurs affectent-ils l'efficacité des médicaments ?\nPeut-on modifier les gènes modificateurs par traitement ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Cognitive+Dysfunction&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes modificateurs",
"description": "Quels types de complications sont liés aux gènes modificateurs ?\nLes gènes modificateurs augmentent-ils les complications ?\nComment gérer les complications liées aux gènes modificateurs ?\nLes complications sont-elles prévisibles avec des gènes modificateurs ?\nLes gènes modificateurs sont-ils impliqués dans des complications spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Cognitive+Dysfunction&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes modificateurs",
"description": "Quels sont les facteurs de risque liés aux gènes modificateurs ?\nLes gènes modificateurs augmentent-ils le risque de maladies ?\nComment évaluer les facteurs de risque génétiques ?\nLes facteurs environnementaux influencent-ils les gènes modificateurs ?\nPeut-on modifier les facteurs de risque liés aux gènes modificateurs ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Cognitive+Dysfunction&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les gènes modificateurs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse génétique et les études d'association sont utilisées pour identifier ces gènes."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes modificateurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de séquençage et les SNP (polymorphismes nucléotidiques) sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils testés en routine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur test n'est pas systématique et dépend des maladies spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les gènes modificateurs par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de détecter les gènes modificateurs, seuls les tests génétiques le peuvent."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les gènes modificateurs dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils aident à comprendre la variabilité des maladies et à affiner le diagnostic."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs affectent-ils les symptômes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer la gravité et la présentation des symptômes d'une maladie."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux gènes modificateurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon la maladie, mais incluent souvent des manifestations cliniques variées."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs causent-ils des symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils modifient l'expression des symptômes causés par d'autres gènes."
}
},
{
"@type": "Question",
"name": "Peut-on prédire les symptômes avec des gènes modificateurs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partiellement, car ils peuvent influencer la sévérité mais pas toujours la présence des symptômes."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils liés à des symptômes spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes modificateurs sont associés à des symptômes spécifiques dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets des gènes modificateurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est complexe, mais une surveillance et un dépistage précoce peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques et des tests peuvent être proposés aux familles à risque."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs nécessitent-ils une prévention ciblée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la prévention peut être ciblée en fonction des gènes modificateurs identifiés."
}
},
{
"@type": "Question",
"name": "Comment la recherche aide-t-elle à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La recherche sur les gènes modificateurs aide à identifier des stratégies préventives efficaces."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs influencent-ils le mode de vie préventif ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent guider les recommandations de mode de vie pour réduire les risques."
}
},
{
"@type": "Question",
"name": "Les traitements ciblent-ils les gènes modificateurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements peuvent être adaptés en fonction des gènes modificateurs identifiés."
}
},
{
"@type": "Question",
"name": "Comment les gènes modificateurs influencent-ils le traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent déterminer la réponse au traitement et la nécessité d'une approche personnalisée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les gènes modificateurs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il n'existe pas de traitements spécifiques, mais des approches personnalisées peuvent être envisagées."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs affectent-ils l'efficacité des médicaments ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer l'efficacité et les effets secondaires des médicaments."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les gènes modificateurs par traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur la thérapie génique, mais ce n'est pas encore courant."
}
},
{
"@type": "Question",
"name": "Quels types de complications sont liés aux gènes modificateurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications varient selon la maladie, incluant des formes plus graves ou résistantes."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs augmentent-ils les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de complications dans certaines conditions génétiques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux gènes modificateurs ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion proactive et personnalisée est essentielle pour minimiser les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles avec des gènes modificateurs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partiellement, car certains gènes modificateurs peuvent indiquer un risque accru de complications."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils impliqués dans des complications spécifiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes modificateurs sont associés à des complications spécifiques dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque liés aux gènes modificateurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des variations génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs augmentent-ils le risque de maladies ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de développer certaines maladies génétiques."
}
},
{
"@type": "Question",
"name": "Comment évaluer les facteurs de risque génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des tests génétiques et des conseils génétiques appropriés."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils les gènes modificateurs ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'environnement peut interagir avec les gènes modificateurs et influencer le risque."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les facteurs de risque liés aux gènes modificateurs ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines modifications du mode de vie peuvent réduire le risque, mais pas tous les facteurs sont modifiables."
}
}
]
}
]
}
Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy....
The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT)....
A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive comp...
Cognitive dysfunction was identified in 35 patients (13%)-14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patient...
Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients t...
The impact of cardiovascular diseases on cognition raises important research questions. The study aimed to investigate the relationship between demographic data, cardiovascular diseases, kidney diseas...
A cross-sectional study of patients with cardiovascular diseases was performed. The Montreal Cognitive Assessment (MoCA) was applied for cognitive evaluation. Based on MoCA three groups were defined: ...
Of 628 patients, 55.2% had mild CD, and the mean age was 67.95 (SD 9.53) years. Cα and Mω were 0.7, indicating good internal consistency. We found a moderate positive correlation between depression an...
Mild CD was the most common in patients with cardiovascular diseases. Older age, lower education, being a non-smoker, and renal dysfunction were risk factors for both mild and advanced CD. Female gend...
Stroke survivors not only suffer from severe motor, speech and neurocognitive deficits, but in many cases also from a "lack of pleasure" and a reduced motivational level. Especially apathy and anhedon...
(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitiv...
One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Vis...
Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acut...
A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infe...
During the last years, a growing number of studies have investigated the link between cognitive dysfunction and rheumatoid arthritis (RA), highlighting the potential pathogenic role of several clinica...
We performed a systematic review using PRISMA (Preferred Reported Items for Systematic Reviews and Meta-analysis) protocol. A systematic search was conducted in the PubMed/MEDLINE, EMBASE, LILACS, Sco...
Five original studies were included, which provided data from 428 participants. Among plasma proteins, SHH was increased and TTR was reduced in patients with mild cognitive impairment; anti-myelin bas...
Despite the relative scarcity of studies on this subject and the heterogeneity of results, we identified possible biomarkers for cognitive deficits in the RA population. Further longitudinal studies a...
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) with a well-documented role in the innate and adaptive immune responses. Interestingly, TLR activation has also been linked to sever...
Cognitive dysfunction is a common adverse consequence of traumatic brain injury (TBI). After brain injury, the brain and other organs trigger a series of complex metabolic changes, including reduced g...
The origin of pre-existing cognitive impairment in stroke patients remains controversial, with a vascular or a degenerative hypothesis....
To determine whether endothelial dysfunction is associated with pre-existing cognitive problems, lesion load and biological anomalies in stroke patients....
Patients originated from the prospective STROKDEM study. The baseline cognitive state, assessed using the IQ-CODE, and risk factors for stroke were recorded at inclusion. Patients with an IQ-CODE scor...
A total of 86 patients were included (52 males; mean age 63.5 ± 11.5 years). Patients with abnormal RHI have hypertension or antihypertensive treatment more often. The baseline IQ-CODE was abnormal in...
A vascular mechanism may be responsible for cognitive problems pre-existing stroke. The measurement of endothelial dysfunction after stroke could become an important element of follow-up, providing an...
There is increasing recognition of the prevalence and impact of cognitive dysfunction (CD) in heart failure (HF) patients. This contemporary review appraises the evidence for epidemiological associati...
CD disproportionately affects heart failure patients, even accounting for known comorbid risk factors, and this may extend to subclinical left ventricular dysfunction. Neuroimaging studies now provide...
Cognitive dysfunction is increasingly recognized as a complication and comorbidity of diabetes, supported by evidence of abnormal brain structure and function. Although few mechanistic metabolic studi...